Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survival
Authors:
- 28 March 2023
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 199 (2) , 355-361
Abstract
Purpose Metaplastic breast carcinoma (MBC) is a rare subtype of breast cancer, defined as mammary carcinoma with squamous or mesenchymal differentiation, that may include spindle cell, chondroid, osseous, or rhabdomyoid differentiation patterns. The implications of MBC recurrence and survival outcomes remains unclear. Methods Cases were ascertained from a prospectively maintained institutional database of patients treated from 1998 to 2015. Patients with MBC were matched 1:1 to non-MBC cases. Cox proportional-hazards models and Kaplan–Meier estimates were used to evaluate outcome differences between cohorts. Results 111 patients with MBC were matched 1:1 with non-MBC patients from an initial set of 2400 patients. Median follow-up time was 8 years. Most patients with MBC received chemotherapy (88%) and radiotherapy (71%). On univariate competing risk regression, MBC was not associated with locoregional recurrence (HR = 1.08; p = 0.8), distant recurrence (HR = 1.65; p = 0.092); disease-free survival (HR = 1.52; p = 0.065), or overall survival (HR = 1.56; p = 0.1). Absolute differences were noted in 8-year disease-free survival (49.6% MBC vs 66.4% non-MBC) and overall survival (61.3% MBC vs 74.4% non-MBC), though neither of these reached statistical significance (p = 0.07 and 0.11, respectively). Conclusion Appropriately-treated MBC may exhibit recurrence and survival outcomes that are difficult to distinguish from those of non-MBC. While prior studies suggest that MBC has a worse natural history than non-MBC triple-negative breast cancer, prudent use of chemotherapy and radiotherapy may narrow these differences, although studies with more power will be required to inform clinical management. Longer follow-up among larger populations may further elucidate the clinical and therapeutic implications of MBC.Keywords
Funding Information
- Lois Green Fund
- NIH/NCI Cancer Center Support Grant (P30CA008748)
This publication has 17 references indexed in Scilit:
- Management and Outcomes in Metaplastic Breast CancerClinical Breast Cancer, 2016
- Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapyBreast Cancer Research and Treatment, 2016
- Metaplastic Carcinoma of the BreastArchives of Pathology & Laboratory Medicine, 2015
- Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based AnalysisAnnals of Surgical Oncology, 2014
- A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd EditionBreast Care, 2013
- Review of Metaplastic Carcinoma of the Breast: Imaging Findings and Pathologic FeaturesJournal of Clinical Imaging Science, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data BaseAnnals of Surgical Oncology, 2006
- Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literatureBreast Cancer Research and Treatment, 2006
- Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005